Zolair study reveals increase in cardiovascular and cerebrovascular problems
스크롤 이동 상태바
Zolair study reveals increase in cardiovascular and cerebrovascular problems
기자명
메디칼라이터팀
입력 2009.07.19 00:00
수정 2009.07.19 23:55
댓글 0
Genentech is carrying out a five-year study so it can access the long-term safety profile of Xolair. The data suggests a disproportionate increase in certain cardiovascular and cerebrovascular problems in patients treated with Xolair compared with the control group not given the drug. The final results of the study are not expected until 21012 and the FDA pointed out that factors other than the drug could be responsible for the increase in heart attack and stroke but mandated the study as part of its post-approval process. The agency is not advising patients to stop taking Zolair and has not recommended any changes to the prescribing information.